AR064996A1 - Derivados de purina - Google Patents
Derivados de purinaInfo
- Publication number
- AR064996A1 AR064996A1 ARP080100274A ARP080100274A AR064996A1 AR 064996 A1 AR064996 A1 AR 064996A1 AR P080100274 A ARP080100274 A AR P080100274A AR P080100274 A ARP080100274 A AR P080100274A AR 064996 A1 AR064996 A1 AR 064996A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- 4alkyl
- optionally substituted
- optionally
- ring
- Prior art date
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 14
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000004434 sulfur atom Chemical group 0.000 abstract 3
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 abstract 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 abstract 1
- 150000003212 purines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Derivados de purina de formula (1), y procedimiento de preparacion. Estos compuestos son utiles como inhibidores de la cinasa JAK3, modulando la actividad inmunologica (enfermedades autoinmunes). Reivindicacion 1: Un compuesto caracterizado por la formula 1,donde: R1 representa fenilo o un heterociclo aromático de 5 o miembros unido al grupo NH a través de un átomo de C que pueden estar opcionalmente fusionados a un anillo de 5 o 6 miembros carbocíclico o heterocíclico saturado, parcialmente insaturado o aromático, donde R1 puede contener de 1 a 4 heteroátomos seleccionados de entre N, O y S, donde uno o más átomos de C o S del anillo de 5 o 6 miembros fusionado pueden estar opcionalmente oxidados formando grupos CO, SO o SO2, y donde R1 puede estar opcionalmente sustituido por uno o más R3; R2 representa fenilo o un heterociclo aromático de 5 o 6 miembros unido al anillo de purina a través de un átomo de C que pueden estar opcionalmente fusionados a un anillo de 5 o 6 miembros carbocíclico o heterocíclico saturado, parcialmente insaturado o aromático, donde R2 puede contener de 1 a 4 heteroátomos seleccionados de entre N, O y S, donde uno o más átomos de C o S del anillo de 5 o 6 miembros fusionado pueden estar opcionalmente oxidados formando grupos CO, SO o SO2, y donde R2 puede estar opcionalmente sustituido por uno o más R4; R3 y R4 representan independientemente alquilo C1-4, alquenilo C2-4, alquinilo C2-4, halogeno, -CN, -NO2, -COR6, -CO2R6, -CONR6R6, -OR6, -OCOR5, -OCONR5R5, -OCO2R5, -SR6, -SO2R5, -SOR5, -SO2NR6R6, -SO2NR7COR5, -NR6R6, -NR7COR6, -NR7CONR6R6, -NR7CO2R5, -NR7SO2R5, -C(=N-OH)R5 o Cy1, donde los grupos alquiIo C1-4, alquenilo C2-4 y alquinilo C2-4 pueden estar opcionalmente sustituidos por uno o más R8 y Cy1 puede estar opcionalmente sustituido por uno o más R9; R5 representa alquilo C1-4, alquenilo C2-4, alquinilo C2-4, o Cy2, donde los grupos alquilo C1-4, alquenilo C2-4, alquinilo C2-4, pueden estar opcionalmente sustituidos por uno o más R10 y Cy2 puede estar opcionalmente sustituido por uno o más R11; R6 representa hidrogeno o R5, R7 representa hidrogeno o alquilo C1-4; R8 representa halogeno, -CN, -NO2, -COR13, -CO2R13, -CONR13R13, -OR13, -OCOR12, - OCONR12R12, -OCO2R12, -SR13, -SO2R12, -SOR12, -SO2NR13R13, -SO2NR7COR12, -NR13R13, -NR7COR13, -NR7CONR13R13, -NR7CO2R12, -NR7SO2R12, -C(=N-OH)R12 o Cy2, donde Cy2 puede estar opcionalmente sustituido por uno o más R11; R9 representa alquilo C1-4 que puede estar opcionalmente sustituido por uno o más R10, o bien R9 representa cualquiera de los significados descritos para R14; R10 representa halogeno, -CN, -NO2, -COR16, -CO2R16, -CONR16R15, -OR16, -OCOR15, -OCONR15R15, -OCO2R15, -SR16, -SO2R15, - SOR15, -SO2NR16R16, -SO2NR7COR15, -NR16R16, -NR7COR16, -NR7CONR16R16, -NR7CO2R15, -NR7SO2R15, -C(=N-OH)R15 o Cy2, donde Cy2 puede estar opcionalmente sustituido por uno o más R11; R11 representa alquilo C1-4, haloC1-4alquilo, alcoxi C1-4-alquilo C1- 4, hidroxiC1-4alquilo, cianoC1-4alquilo o cualquiera de los significados descritos para R14; R12 representa alquilo C1-4, haloC1-4alquilo, alcoxi C1-4-alquilo C1-4, hidroxiC1-4alquilo, cianoC1-4alquilo, Cy3-alquilo C1-4 o Cy2, donde Cy2 puede estar opcionalmente sustituido por uno o más R11; R13 representa hidrogeno o R12; R14 representa halogeno, -CN, -NO2, -COR18, -CO2R18, -CONR18R18, -OR18, -OCOR17, -OCONR17R17, -OCO2R17, -SR18, -SO2R17, -SOR17, -SO2NR18R18, -SO2NR7COR17, -NR18R18, - NR7COR18, -NR7CONR18R18, -NR7CO2R17, -NR7SO2R17 o -C(=N-OH)R17; R15 representa alquilo C1-4, haloC1-4alquilo, alcoxi C1-4-alquilo C1-4, hidroxiC1-4alquilo, cianoC1-4alquilo o Cy2, donde Cy2 puede estar opcionalmente sustituido por uno o más R11; R16 representa hidrogeno o R15; R17 representa alquilo C1-4, haloC1-4alquilo, alcoxi C1-4-aIquilo C1-4, hidroxiC1-4alquilo o cianoC1-4alquilo; R18 representa hidrogeno o R17; o bien dos grupos R17 o dos grupos R18 sobre un mismo átomo de N pueden estar unidos completando, junto con el átomo de N, un anillo saturado de 5 a 6 átomos, que puede contener adicionalmente uno o dos heteroátomos seleccionados de entre N, S y O y que puede estar opcionalmente sustituido por uno o más grupos alquilo C1-4; Cy1 y Cy2 representan independientemente un anillo carbocíclico monociclico de 3 a 7 miembros o bicíclico de 8 a 12 miembros que puede ser saturado, parcialmente insaturado o aromático, y que puede contener opcionalmente de 1 a 4 heteroátomos seleccionados de entre N, S y O, donde dicho anillo puede estar unido al resto de la molécula a través de cualquier átomo de C o N disponible, y donde uno o más átomos de C o S del anillo pueden estar opcionalmente oxidados formando grupos CO, SO o SO2; Cy3 representa un anillo seleccionado de entre (a)-(c); y R19 representa hidrogeno o alquilo C1-4; o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07381005 | 2007-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064996A1 true AR064996A1 (es) | 2009-05-06 |
Family
ID=38042749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100274A AR064996A1 (es) | 2007-01-23 | 2008-01-23 | Derivados de purina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100204187A1 (es) |
| EP (1) | EP2118105A1 (es) |
| JP (1) | JP2010526027A (es) |
| KR (1) | KR20090101281A (es) |
| CN (1) | CN101589043A (es) |
| AR (1) | AR064996A1 (es) |
| AU (1) | AU2008208801A1 (es) |
| BR (1) | BRPI0806811A2 (es) |
| CA (1) | CA2674875A1 (es) |
| CL (1) | CL2008000192A1 (es) |
| MX (1) | MX2009007302A (es) |
| PE (1) | PE20090054A1 (es) |
| RU (1) | RU2009131738A (es) |
| TW (1) | TW200902017A (es) |
| WO (1) | WO2008090181A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2134723B1 (en) * | 2007-03-07 | 2017-07-12 | Boehringer Ingelheim International GmbH | 2,6 diamino-9h-purine derivatives and their use in the treatment of proliferative diseases |
| US20100144756A1 (en) * | 2007-07-13 | 2010-06-10 | Bolea Christelle | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| ES2535166T3 (es) * | 2007-09-04 | 2015-05-06 | The Scripps Research Institute | Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas |
| JP5647998B2 (ja) | 2009-03-13 | 2015-01-07 | カトリーケ ユニバーシテイト ルーヴェン、ケー．ユー． ルーヴェン アール アンド ディー | 免疫抑制剤としてのチアゾロピリミジン調節因子 |
| US8754080B2 (en) | 2009-04-03 | 2014-06-17 | Verastem, Inc. | Pyrimidine substituted purine compounds as kinase (S) inhibitors |
| MX2012004313A (es) * | 2009-10-12 | 2012-07-20 | Myrexis Inc | Compuestos de amino-pirimidina como inhibidores de cinasa 1 de union a tank (tbk1) y/o i-kappa-b-cinasa epsilon (ikk epsilon). |
| JP5739446B2 (ja) * | 2009-12-18 | 2015-06-24 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| GB201012889D0 (en) | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
| GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
| NZ608069A (en) | 2010-10-06 | 2014-06-27 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
| JP6147727B2 (ja) * | 2011-04-01 | 2017-06-14 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体 |
| WO2012172043A1 (en) | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| US9688661B2 (en) * | 2012-08-02 | 2017-06-27 | Nerviano Medical Sciences S.R.L. | Substituted pyrroles active as kinases inhibitors |
| JP5746777B2 (ja) * | 2014-01-21 | 2015-07-08 | ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． | キナーゼ阻害剤としてのピリミジン置換プリン化合物 |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| US10040781B2 (en) | 2014-09-26 | 2018-08-07 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
| EP3053920B1 (en) * | 2015-02-05 | 2020-04-08 | AB Science | Compounds with anti-tumoral activity |
| BR112017002594A2 (pt) | 2015-12-17 | 2017-12-19 | Gilead Sciences Inc | compostos inibidores de cinase de ligação de tank |
| EP3524602A1 (en) | 2016-09-07 | 2019-08-14 | Shanghai Haihe Pharmaceutical Co., Ltd. | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof |
| JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| EP3947382B1 (en) * | 2019-03-26 | 2025-09-24 | Academia Sinica | Compounds for uses in pharmacological induction of hbf for treatment of sickle cell disease and beta-thalassemia |
| CN114685507B (zh) * | 2022-04-06 | 2024-01-12 | 山东大学 | 嘌呤胺衍生物类cdk2抑制剂及其制备方法和应用 |
| CN117247387A (zh) * | 2022-06-16 | 2023-12-19 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003288994A1 (en) * | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| US7476670B2 (en) * | 2003-02-18 | 2009-01-13 | Aventis Pharma S.A. | Purine derivatives, method for preparing, pharmaceutical compositions and novel use |
| FR2851248B1 (fr) * | 2003-02-18 | 2005-04-08 | Aventis Pharma Sa | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
| AU2004225977B2 (en) * | 2003-03-25 | 2011-03-24 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| EP1610793A2 (en) * | 2003-03-25 | 2006-01-04 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| GB0407723D0 (en) * | 2004-04-05 | 2004-05-12 | Novartis Ag | Organic compounds |
| US20060247263A1 (en) * | 2005-04-19 | 2006-11-02 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
-
2008
- 2008-01-23 BR BRPI0806811-9A patent/BRPI0806811A2/pt not_active IP Right Cessation
- 2008-01-23 US US12/524,234 patent/US20100204187A1/en not_active Abandoned
- 2008-01-23 AU AU2008208801A patent/AU2008208801A1/en not_active Abandoned
- 2008-01-23 JP JP2009546749A patent/JP2010526027A/ja not_active Withdrawn
- 2008-01-23 CN CNA2008800029892A patent/CN101589043A/zh active Pending
- 2008-01-23 PE PE2008000169A patent/PE20090054A1/es not_active Application Discontinuation
- 2008-01-23 TW TW097102513A patent/TW200902017A/zh unknown
- 2008-01-23 CA CA002674875A patent/CA2674875A1/en not_active Abandoned
- 2008-01-23 RU RU2009131738/04A patent/RU2009131738A/ru not_active Application Discontinuation
- 2008-01-23 MX MX2009007302A patent/MX2009007302A/es not_active Application Discontinuation
- 2008-01-23 KR KR1020097015419A patent/KR20090101281A/ko not_active Withdrawn
- 2008-01-23 WO PCT/EP2008/050769 patent/WO2008090181A1/en not_active Ceased
- 2008-01-23 EP EP08701649A patent/EP2118105A1/en not_active Withdrawn
- 2008-01-23 CL CL200800192A patent/CL2008000192A1/es unknown
- 2008-01-23 AR ARP080100274A patent/AR064996A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100204187A1 (en) | 2010-08-12 |
| MX2009007302A (es) | 2009-07-15 |
| EP2118105A1 (en) | 2009-11-18 |
| PE20090054A1 (es) | 2009-01-26 |
| CL2008000192A1 (es) | 2008-07-25 |
| JP2010526027A (ja) | 2010-07-29 |
| WO2008090181A1 (en) | 2008-07-31 |
| BRPI0806811A2 (pt) | 2011-09-13 |
| KR20090101281A (ko) | 2009-09-24 |
| CN101589043A (zh) | 2009-11-25 |
| AU2008208801A1 (en) | 2008-07-31 |
| TW200902017A (en) | 2009-01-16 |
| RU2009131738A (ru) | 2011-02-27 |
| CA2674875A1 (en) | 2008-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064996A1 (es) | Derivados de purina | |
| AR065901A1 (es) | Derivados de pirrolipirimidina | |
| AR074870A1 (es) | Derivados de pirazolo (1,5-a ) piridina | |
| AR073397A1 (es) | Derivados de (r) -3- (n,n-dimetilamino) pirrolidina | |
| CO6321261A2 (es) | Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados de pirazolo [1,5-a] pirimidinas procedimientos para su preparacion y usos de los mismos | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR041250A1 (es) | Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR078833A1 (es) | Derivados de heteroarilos que contienen nitrogeno como inhibidores dela cinasa jak3 | |
| PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| AR061603A1 (es) | Derivados de etenilcarboxamidas microbicidas | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| CO6190554A2 (es) | Compuestos de 4-hidroxi-2-oxo-2, 3-dihidro-1, 3-benzotiazol-7il para la modulacion de la actividad del adrenoreceptor beta2 | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| RU2008142600A (ru) | Органическое соединение | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| AR105522A1 (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor | |
| AR058388A1 (es) | DERIVADOS DE COMPUESTOS AROMATICOS SUSTITUIDOS uTILES PARA TRASTORNOS RESPIRATORIOS , COMPOSICIONES FARMACÉUTICAS Y PROCESOS PARA SU PREPARACIoN | |
| AR067945A1 (es) | Pirimidinas biciclicas fusionadas | |
| AR051966A1 (es) | Derivados de acido fenoxiacetico utiles para el tratamiento de enfermedades respiratorias | |
| AR058010A1 (es) | Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |